CA3135196A1 - Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers - Google Patents
Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers Download PDFInfo
- Publication number
- CA3135196A1 CA3135196A1 CA3135196A CA3135196A CA3135196A1 CA 3135196 A1 CA3135196 A1 CA 3135196A1 CA 3135196 A CA3135196 A CA 3135196A CA 3135196 A CA3135196 A CA 3135196A CA 3135196 A1 CA3135196 A1 CA 3135196A1
- Authority
- CA
- Canada
- Prior art keywords
- hedgehog pathway
- cancer
- inhibitor
- dependent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 112
- 239000003112 inhibitor Substances 0.000 title claims abstract description 110
- 230000037361 pathway Effects 0.000 title claims abstract description 102
- 230000001419 dependent effect Effects 0.000 title claims abstract description 57
- 241000289669 Erinaceus europaeus Species 0.000 title claims abstract 19
- 101710082924 Atypical protein kinase C Proteins 0.000 title description 104
- 238000000034 method Methods 0.000 claims abstract description 77
- 230000035755 proliferation Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 96
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 71
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 65
- 201000011510 cancer Diseases 0.000 claims description 56
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 11
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 10
- 229960000237 vorinostat Drugs 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 102000003964 Histone deacetylase Human genes 0.000 claims description 7
- 108090000353 Histone deacetylase Proteins 0.000 claims description 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- 230000035899 viability Effects 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 3
- 238000001815 biotherapy Methods 0.000 claims description 3
- 230000011664 signaling Effects 0.000 abstract description 32
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 230000005764 inhibitory process Effects 0.000 abstract description 14
- 206010027476 Metastases Diseases 0.000 abstract description 12
- 230000009401 metastasis Effects 0.000 abstract description 12
- 230000005907 cancer growth Effects 0.000 abstract description 2
- 108010008359 protein kinase C lambda Proteins 0.000 abstract description 2
- 244000060234 Gmelina philippensis Species 0.000 description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 238000002560 therapeutic procedure Methods 0.000 description 27
- 201000010099 disease Diseases 0.000 description 25
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000004913 activation Effects 0.000 description 17
- 229940127084 other anti-cancer agent Drugs 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 8
- 208000000172 Medulloblastoma Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 7
- -1 amino acid salts Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000009826 neoplastic cell growth Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000004797 therapeutic response Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000008410 smoothened signaling pathway Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000003174 Brain Neoplasms Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108090000031 Hedgehog Proteins Proteins 0.000 description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000031995 Gorlin syndrome Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 3
- 102000012850 Patched-1 Receptor Human genes 0.000 description 3
- 108010065129 Patched-1 Receptor Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 3
- 229940069510 parthenolide Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 229960004449 vismodegib Drugs 0.000 description 3
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 3
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010002156 Depsipeptides Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000004364 Myogenin Human genes 0.000 description 2
- 108010056785 Myogenin Proteins 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000051107 Paraechinus aethiopicus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 2
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- 229940054066 benzamide antipsychotics Drugs 0.000 description 2
- 150000003936 benzamides Chemical class 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229950005259 dacinostat Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
- OZWGHIQPWZHYPG-UHFFFAOYSA-N ethyl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate Chemical compound CCOC(=O)C1=C(N)SC=C1C1=CC=C(OC)C(OC)=C1 OZWGHIQPWZHYPG-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229950010415 givinostat Drugs 0.000 description 2
- 230000009459 hedgehog signaling Effects 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 230000007434 lytic lesion Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229950007812 mocetinostat Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229930009674 sesquiterpene lactone Natural products 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 108010060596 trapoxin B Proteins 0.000 description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 240000001837 Euphorbia peplus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010024124 Histone Deacetylase 1 Proteins 0.000 description 1
- 108010023981 Histone Deacetylase 2 Proteins 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 102000000017 Patched Receptors Human genes 0.000 description 1
- 108010069873 Patched Receptors Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100021557 Protein kinase C iota type Human genes 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101150056682 Smo gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101150094224 Sufu gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000002922 epistatic effect Effects 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 210000002353 nuclear lamina Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000038009 orphan disease Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950011110 tacedinaline Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Methods for treating hedgehog pathway-dependent cancers are provided. Aspects of the methods include the inhibition of hedgehog pathway-dependent cancer growth, proliferation, or metastasis that is promoted by hedgehog pathway signaling. In particular, methods of treating hedgehog pathway-dependent cancers with inhibitors of atypical protein kinase C iota, such as the compounds below, are disclosed.
Description
INHIBITORS OF ATYPICAL PROTEIN KINASE C AND THEIR USE IN
TREATING HEDGEHOG PATHWAY-DEPENDENT CANCERS
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0001] This invention was made with Government support under contract AR054780 awarded by the National Institutes of Health. The Government has certain rights in the invention.
FIELD OF THE INVENTION
TREATING HEDGEHOG PATHWAY-DEPENDENT CANCERS
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0001] This invention was made with Government support under contract AR054780 awarded by the National Institutes of Health. The Government has certain rights in the invention.
FIELD OF THE INVENTION
[0002] This invention pertains to therapeutics for treating hedgehog pathway-dependent cancers and disorders. In particular, the invention relates to methods of treating hedgehog pathway-dependent cancers and disorders with inhibitors of atypical protein kinase C (aPKC) iota.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003] The Hedgehog (Hh) signaling pathway plays a critical role in development and tumorigenesis across metazoa. Three mammalian Hh genes have been identified:
Sonic hedgehog (SHh), Desert hedgehog (DHh), and Indian hedgehog (IHh). These proteins are secreted proteins that act by antagonizing the receptor Patched (Ptch1 or Ptch2 in humans).
Ptch acts in part by antagonizing the activity of Smoothened (Smo), a G-protein coupled receptor that activates the transcription factor Gli. When Shh binds to Ptch, Ptch-mediated repression of Smo is relieved, allowing Smo to promote Gli-dependent transcription. During development, Hh induced Smo activity promotes proliferation, migration, and differentiation of progenitor cells to pattern organ development. However, dysregulation of Hh pathway signaling, for example by inactivating mutations of Ptch or activating mutations of Smo, has been associated with cancer (Toftgard, R. Hedgehog signaling in cancer. Cell Mol. Life Sci., 57: 1720-1731 (2000)). Induction of Hh target genes is required for tumor growth and maintenance in tumor epithelia, and Hh pathway signaling has been implicated in tumor metastasis of a number of epithelial tumors. For example, basal cell carcinoma (BCC) initiation and expansion requires high levels of Hh pathway signaling.
Sonic hedgehog (SHh), Desert hedgehog (DHh), and Indian hedgehog (IHh). These proteins are secreted proteins that act by antagonizing the receptor Patched (Ptch1 or Ptch2 in humans).
Ptch acts in part by antagonizing the activity of Smoothened (Smo), a G-protein coupled receptor that activates the transcription factor Gli. When Shh binds to Ptch, Ptch-mediated repression of Smo is relieved, allowing Smo to promote Gli-dependent transcription. During development, Hh induced Smo activity promotes proliferation, migration, and differentiation of progenitor cells to pattern organ development. However, dysregulation of Hh pathway signaling, for example by inactivating mutations of Ptch or activating mutations of Smo, has been associated with cancer (Toftgard, R. Hedgehog signaling in cancer. Cell Mol. Life Sci., 57: 1720-1731 (2000)). Induction of Hh target genes is required for tumor growth and maintenance in tumor epithelia, and Hh pathway signaling has been implicated in tumor metastasis of a number of epithelial tumors. For example, basal cell carcinoma (BCC) initiation and expansion requires high levels of Hh pathway signaling.
[0004] There remains a need for better methods of treating Hh pathway-associated cancers and disorders.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0005]
Methods for treating hedgehog pathway-dependent cancers are provided. Aspects of the methods include the inhibition of hedgehog pathway-dependent cancer growth, proliferation, and/or metastasis that is promoted by hedgehog pathway signaling. In particular, methods of treating hedgehog pathway-dependent cancers with inhibitors of aPKC
iota are disclosed.
Methods for treating hedgehog pathway-dependent cancers are provided. Aspects of the methods include the inhibition of hedgehog pathway-dependent cancer growth, proliferation, and/or metastasis that is promoted by hedgehog pathway signaling. In particular, methods of treating hedgehog pathway-dependent cancers with inhibitors of aPKC
iota are disclosed.
[0006] In one aspect, a method of treating a subject for a hedgehog pathway-dependent cancer is provided, the method comprising administering to the subject a therapeutically effective amount of a composition comprising CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof.
[0007] In certain embodiments, the cancer comprises a constitutively active hedgehog pathway. In one embodiment, the cancer is basal cell carcinoma (BCC). In some embodiments, the cancer is metastatic.
[0008]
Multiple cycles of treatment may be administered to the subject over a period of time.
For example, treatment may be administered to the subject for at least 3 months, at least 6 months, at least 9 months, or at least 12 months, or longer. Preferably, multiple cycles of treatment are administered to the subject for a time period sufficient to effect at least a partial tumor response, or more preferably, a complete tumor response. In certain embodiment, the composition comprising the CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, is administered according to a daily dosing regimen or intermittently.
Multiple cycles of treatment may be administered to the subject over a period of time.
For example, treatment may be administered to the subject for at least 3 months, at least 6 months, at least 9 months, or at least 12 months, or longer. Preferably, multiple cycles of treatment are administered to the subject for a time period sufficient to effect at least a partial tumor response, or more preferably, a complete tumor response. In certain embodiment, the composition comprising the CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, is administered according to a daily dosing regimen or intermittently.
[0009] In certain embodiments, the method further comprises administering additional anti-cancer therapy such as, but not limited to, surgery, chemotherapy, radiation therapy, immunotherapy, biologic therapy, or a combination thereof.
[0010] In certain embodiments, the composition that is administered further comprises a pharmaceutically acceptable excipient.
[0011] In certain embodiments, the method further comprises administering a histone deacetylase (HDAC) inhibitor in combination with the CR10422839 or CR10364436, or the pharmaceutically acceptable salt thereof. Exemplary HDAC inhibitors include hydroxamic acids such as vorinostat, belinostat, panobinostat, givinostat, dacinostat (LA0824), and trichostatin A; sesquiterpene lactones such as parthenolide, cyclic tetrapeptides such as trapoxin B; depsipeptides such as romidepsin, and benzamides such as entinostat (MS-275), tacedinaline (CI994), and mocetinostat. In one embodiment, the HDAC inhibitor is vorinostat.
[0012] In certain embodiments, the subject is mammalian, for example a human or nonhuman primate, rodent, farm animal, or pet.
[0013] In certain embodiments, the CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce viability of hedgehog pathway-dependent cancerous cells in the subject.
[0014] In certain embodiments, the CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce production of Gli 1 mRNA in hedgehog pathway-dependent cancerous cells in the subject.
[0015] In certain embodiments, the CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce growth and cell proliferation of hedgehog pathway-dependent cancerous cells in the subject.
[0016] In another aspect, a method of inhibiting growth or proliferation of a hedgehog pathway-dependent cancerous cell is provided, the method comprising contacting the hedgehog pathway-dependent cancerous cell with an effective amount of CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof.
[0017] In certain embodiments, the hedgehog pathway-dependent cancerous cell is a BCC
cell.
cell.
[0018] In certain embodiments, the hedgehog pathway-dependent cancerous cell comprises a constitutively active hedgehog pathway.
[0019] In certain embodiments, the hedgehog pathway-dependent cancerous cell is in vivo or in vitro.
[0020] In certain embodiments, the hedgehog pathway-dependent cancerous cell is a mammalian (e.g., a human or nonhuman primate, rodent, farm animal, or pet) cancerous cell.
[0021] In certain embodiments, the method further comprises contacting the hedgehog pathway-dependent cancerous cell with an HDAC inhibitor.
[0022] In another aspect, a composition comprising CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, for use in the treatment of a hedgehog pathway-dependent cancer is provided. In some embodiments, the composition further comprises a HDAC inhibitor. In one embodiment, the HDAC inhibitor is vorinostat.
[0023] In another aspect, a composition comprising CR10422839 or CR10364436, or a pharmaceutically acceptable salt thereof, for use in the treatment of basal cell carcinoma is provided. In some embodiments, the composition further comprises a HDAC
inhibitor. In one embodiment, the HDAC inhibitor is vorinostat.
BRIEF DESCRIPTION OF THE DRAWINGS
inhibitor. In one embodiment, the HDAC inhibitor is vorinostat.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures.
[0025] FIGS.
1A-1D show that atypical protein kinase iota (aPKCI) inhibitors modulate BCC
cell viability. The effects of the compounds CR10422839 and CRT 0364436 on BCC
viability were tested in a murine BCC cell line (BSC1) and compared to results with a known peptide inhibitor, PSI, which was previously described in Mirza et al. (JCI Insight (2017) 2(21):e97071).
BSCI cell viability is shown after treatment with the aPKC inhibitors, PSI
(FIG. 1A), CR10329868 (FIG. 1B), CR10364436 (FIG. 1C), or CR10422839 (FIG. 1D) at concentrations of 1 gm and 10 gm.
1A-1D show that atypical protein kinase iota (aPKCI) inhibitors modulate BCC
cell viability. The effects of the compounds CR10422839 and CRT 0364436 on BCC
viability were tested in a murine BCC cell line (BSC1) and compared to results with a known peptide inhibitor, PSI, which was previously described in Mirza et al. (JCI Insight (2017) 2(21):e97071).
BSCI cell viability is shown after treatment with the aPKC inhibitors, PSI
(FIG. 1A), CR10329868 (FIG. 1B), CR10364436 (FIG. 1C), or CR10422839 (FIG. 1D) at concentrations of 1 gm and 10 gm.
[0026] FIGS.
2A and 2B show the effects of treating the murine BCC cell line (BSC1) with PSI, CR10329868, CR10422839, or CR10364436 on expression levels of Gli 1 mRNA, a marker of Shh pathway output, which was measured to further document the inhibition of BCC
growth and Shh pathway signaling. Results are shown after 6 hours (FIG. 2A) or 24 hours (FIG. 2B) of treatment with the compounds at concentrations of 1 gm and 10 gm.
2A and 2B show the effects of treating the murine BCC cell line (BSC1) with PSI, CR10329868, CR10422839, or CR10364436 on expression levels of Gli 1 mRNA, a marker of Shh pathway output, which was measured to further document the inhibition of BCC
growth and Shh pathway signaling. Results are shown after 6 hours (FIG. 2A) or 24 hours (FIG. 2B) of treatment with the compounds at concentrations of 1 gm and 10 gm.
[0027] FIGS.
3A-3B show the chemical structures and properties of the aPKCI inhibitors, CR10364436/TEV-44229 (FIG. 3A) and CR10422839/TEV-47448 (FIG. 3B).
DETAILED DESCRIPTION OF THE INVENTION
3A-3B show the chemical structures and properties of the aPKCI inhibitors, CR10364436/TEV-44229 (FIG. 3A) and CR10422839/TEV-47448 (FIG. 3B).
DETAILED DESCRIPTION OF THE INVENTION
[0028]
Before the present methods and compositions are described, it is to be understood that this invention is not limited to particular method or composition described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Before the present methods and compositions are described, it is to be understood that this invention is not limited to particular method or composition described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0029] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention.
The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0030]
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.
[0031] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention.
Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
[0032] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the inhibitor" includes reference to one or more inhibitors and equivalents thereof, e.g. compounds or drugs, known to those skilled in the art, and so forth.
[0033] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0034] The term "about", particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.
[0035] The terms "tumor, "cancer" and "neoplasia" are used interchangeably and refer to a cell or population of cells whose growth, proliferation or survival is greater than growth, proliferation or survival of a normal counterpart cell, e.g. a cell proliferative, hyperproliferative or differentiative disorder. Typically, the growth is uncontrolled. The term "malignancy" refers to invasion of nearby tissue. The term "metastasis" or a secondary, recurring or recurrent tumor, cancer or neoplasia refers to spread or dissemination of a tumor, cancer or neoplasia to other sites, locations or regions within the subject, in which the sites, locations or regions are distinct from the primary tumor or cancer. Neoplasia, tumors and cancers include benign, malignant, metastatic and non-metastatic types, and include any stage (I, II, Ill, IV or V) or grade (G1, G2, G3, etc.) of neoplasia, tumor, or cancer, or a neoplasia, tumor, cancer or metastasis that is progressing, worsening, stabilized or in remission. In particular, the terms "tumor, "cancer" and "neoplasia" include carcinomas, such as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, and small cell carcinoma.
[0036] The term "hedgehog pathway-dependent cancer" includes any cancer dependent on activation of the hedgehog pathway or associated with aberrant activation of the Hedgehog pathway such as, but not limited to, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, small cell lung cancer, retinoblastoma, gastric and upper gastrointestinal track cancer, osteosarcoma, pancreatic cancer, breast cancer, colon cancer, ovarian cancer, brain cancer, mammary gland cancer, thyroid cancer, and prostate cancer.
[0037] By "anti-tumor activity" is intended a reduction in the rate of cell proliferation, and hence a decline in growth rate of an existing tumor or in a tumor that arises during therapy, and/or destruction of existing neoplastic (tumor) cells or newly formed neoplastic cells, and hence a decrease in the overall size of a tumor during therapy. Such activity can be assessed using animal models, such as xenograft models of human renal cell carcinoma. See, e.g., Pulkkanen et al.. in Vivo (2000) 14:393-400 and Everitt et al., Toxicol. Lett.
(1995) 82-83:621-625 for a description of animal models,
(1995) 82-83:621-625 for a description of animal models,
[0038] By "therapeutically effective dose or amount" of an aPKC iota inhibitor (e.g., CR10422839 or CR10364436) is intended an amount that, when the aPKC iota inhibitor is administered, or when in addition a histone deacetylase inhibitor (e.g., vorinostat) is administered in combination with the aPKC iota inhibitor, as described herein, brings about a positive therapeutic response, such as anti-tumor activity. Additionally, an "effective amount"
of an aPKC iota inhibitor may inhibit growth, proliferation, and/or metastasis of hedgehog pathway-dependent cancerous cells, and/or reduce production of Gli 1 mRNA in hedgehog pathway-dependent cancerous cells, and/or reduce viability of hedgehog pathway-dependent cancerous cells.
of an aPKC iota inhibitor may inhibit growth, proliferation, and/or metastasis of hedgehog pathway-dependent cancerous cells, and/or reduce production of Gli 1 mRNA in hedgehog pathway-dependent cancerous cells, and/or reduce viability of hedgehog pathway-dependent cancerous cells.
[0039] The term "tumor response" as used herein means a reduction or elimination of all measurable lesions. The criteria for tumor response are based on the WHO
Reporting Criteria [WHO Offset Publication, 48-World Health Organization, Geneva, Switzerland, (1979)].
Ideally, all uni- or bidimensionally measurable lesions should be measured at each assessment. When multiple lesions are present in any organ, such measurements may not be possible and, under such circumstances, up to 6 representative lesions should be selected, if available.
Reporting Criteria [WHO Offset Publication, 48-World Health Organization, Geneva, Switzerland, (1979)].
Ideally, all uni- or bidimensionally measurable lesions should be measured at each assessment. When multiple lesions are present in any organ, such measurements may not be possible and, under such circumstances, up to 6 representative lesions should be selected, if available.
[0040] The term "complete response" (CR) as used herein means a complete disappearance of all clinically detectable malignant disease, determined by 2 assessments at least 4 weeks apart.
[0041] The term "partial response" (PR) as used herein means a 50% or greater reduction from baseline in the sum of the products of the longest perpendicular diameters of all measurable disease without progression of evaluable disease and without evidence of any new lesions as determined by at least two consecutive assessments at least four weeks apart.
Assessments should show a partial decrease in the size of lytic lesions, recalcifications of lytic lesions, or decreased density of blastic lesions. It is not unusual to observe transient inflammation in sites of metastatic disease. Individual lesions which appear to increase in size do not necessarily disqualify a PR unless the increase is documented on two sequential measurements taken at least 28 days apart.
Assessments should show a partial decrease in the size of lytic lesions, recalcifications of lytic lesions, or decreased density of blastic lesions. It is not unusual to observe transient inflammation in sites of metastatic disease. Individual lesions which appear to increase in size do not necessarily disqualify a PR unless the increase is documented on two sequential measurements taken at least 28 days apart.
[0042]
"Pharmaceutically acceptable excipient or carrier" refers to an excipient that may optionally be included in compositions that causes no significant adverse toxicological effects to the patient.
"Pharmaceutically acceptable excipient or carrier" refers to an excipient that may optionally be included in compositions that causes no significant adverse toxicological effects to the patient.
[0043]
"Pharmaceutically acceptable salt" includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts. Similarly salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).
"Pharmaceutically acceptable salt" includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts. Similarly salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).
[0044] As used herein, the terms "treatment," "treating," and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. "Treatment," as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) increasing survival time; (b) decreasing the risk of death due to the disease; (c) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (d) inhibiting the disease, i.e., arresting its development (e.g., reducing the rate of disease progression); and (e) relieving the disease, i.e., causing regression of the disease.
[0045]
"Substantially purified" generally refers to isolation of a substance (e.g., compound, molecule, agent) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample, a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample.
"Substantially purified" generally refers to isolation of a substance (e.g., compound, molecule, agent) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample, a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample.
[0046] The terms "subject," "individual," and "patient," are used interchangeably herein and refer to any mammalian subject for whom diagnosis, prognosis, treatment, or therapy is desired, particularly humans. "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, etc. In some cases, the methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters; primates, and transgenic animals.
Methods
Methods
[0047]
Methods for treating hedgehog pathway-dependent cancers with inhibitors of aPKC
iota are disclosed. In some embodiments, an inhibitor of aPKC iota is used in combination with an inhibitor of HDACI . Without being bound by a particular theory, aPKC
phosphorylates the GLII transcription factor resulting in chromatin association of GLII and activation of gene transcription leading to activation of the hedgehog pathway. GLII activity is controlled by regulation of its nuclear import. That is, GLII moves between the nuclear lamina where it is inactive and the nucleoplasm where it is active. The mechanism by which aPKC
iota activates GUI appears to involve recruitment of HDACI to GLII , wherein GUI is activated by HDACI -mediated deacetylation. Thus, inhibitors of aPKC iota as well as inhibitors of HDACI may be useful in treating hedgehog pathway-dependent cancers.
Methods for treating hedgehog pathway-dependent cancers with inhibitors of aPKC
iota are disclosed. In some embodiments, an inhibitor of aPKC iota is used in combination with an inhibitor of HDACI . Without being bound by a particular theory, aPKC
phosphorylates the GLII transcription factor resulting in chromatin association of GLII and activation of gene transcription leading to activation of the hedgehog pathway. GLII activity is controlled by regulation of its nuclear import. That is, GLII moves between the nuclear lamina where it is inactive and the nucleoplasm where it is active. The mechanism by which aPKC
iota activates GUI appears to involve recruitment of HDACI to GLII , wherein GUI is activated by HDACI -mediated deacetylation. Thus, inhibitors of aPKC iota as well as inhibitors of HDACI may be useful in treating hedgehog pathway-dependent cancers.
[0048] While the methods of the invention are directed to treatment of an existing tumor, it is recognized that the methods may be useful in preventing further tumor outgrowths arising during therapy.
Inhibitors of Atypical Protein Kinase C Iota
Inhibitors of Atypical Protein Kinase C Iota
[0049] As explained above, the methods of the present invention include administering an inhibitor of aPKC iota. Exemplary inhibitors of aPKC iota include 0RT0422839 (TEV-47448) and 0RT0364436 (TEV-44229), or a pharmaceutically acceptable salt thereof.
0RT0422839 has the chemical formula:
....... /
0RT0364436 has the chemical formula:
H
N
0RT0422839 has the chemical formula:
....... /
0RT0364436 has the chemical formula:
H
N
[0050] Such aPKC iota inhibitors have anti-tumor activity in treating hedgehog pathway-dependent cancers. In particular, these aPKC iota inhibitors have the ability to inhibit growth, proliferation, and metastasis of hedgehog pathway-dependent cancerous cells, reduce production of Gli 1 mRNA in hedgehog pathway-dependent cancerous cells, and reduce viability of hedgehog pathway-dependent cancerous cells (see Examples).
Inhibitors of HDAC1
Inhibitors of HDAC1
[0051] In certain embodiments, combination therapy is performed with an aPKC iota inhibitor and an HDAC1 inhibitor. Exemplary HDAC1 inhibitors include hydroxamic acids such as vorinostat, belinostat, panobinostat, givinostat, dacinostat (LA0824), and trichostatin A;
sesquiterpene lactones such as parthenolide, cyclic tetrapeptides such as trapoxin B;
depsipeptides such as romidepsin, and benzamides such as entinostat (MS-275), tacedinaline (01994), and mocetinostat. In some embodiments, an inhibitor that selectively inhibits HDAC1 without affecting other classes of HDACs is used such as parthenolide.
Inhibition of Hedgehog Signaling Pathway
sesquiterpene lactones such as parthenolide, cyclic tetrapeptides such as trapoxin B;
depsipeptides such as romidepsin, and benzamides such as entinostat (MS-275), tacedinaline (01994), and mocetinostat. In some embodiments, an inhibitor that selectively inhibits HDAC1 without affecting other classes of HDACs is used such as parthenolide.
Inhibition of Hedgehog Signaling Pathway
[0052] Use of aPKC iota inhibitors alone or in combination with HDAC inhibitors, as described herein, inhibits Hh pathway signaling. By inhibited, it is meant the activity of the pathway is reduced, suppressed, decreased, attenuated or antagonized. For example, it may be desirous to inhibit Hh pathway signaling with an aPKC iota inhibitor and/or a HDAC
inhibitor in a cell (e.g., cancerous cell) in which the Hh pathway is hyperactive or constitutively active, e.g. in a cell that comprises an activating mutation in a Smo gene or an inactivating mutation in a Ptch or SUFU gene, or a cell in which pathway activators such as SHH/IHH ligands, SMO or GLI1/2 are overexpressed. Other mutations that promote aberrant activation of the hedgehog signaling pathway are well known and can be readily determined by one of skill in the art. For a review of mutations associated with aberrant activation of hedgehog signaling, particularly mutations implicated in cancer, see, e.g., Pellegrini et al. (2017) Int. J.
Mol. Sci. 18(11) pii:
E2485, Bao et al. (2018) Mol. Nutr. Food Res. 62(1), Levanat et al. (2017) Curr. Pharm. Des.
23(1):73-94, Laukkanen et al. (2016) Anticancer Agents Med. Chem. 16(3):309-317, Suzman et al. (2015) Cancers (Basel). 7(4):1983-1993, Holikova et al. (2004) Int. J.
Dermatol.
43(12):865-869, Wetmore (2003) Curr. Opin. Genet. Dev. 13(1):34-42, Bale (2002) Annu.
Rev. Genomics Hum. Genet. 3:47-65, Lacour et al. (2002) Br. J. Dermatol. 146 Suppl 61:17-19, Wicking et al. (2001) Cancer Lett. 173(1):1-7, and Daya-Grosjean et al.
(2005) Cancer Lett. 225(2):181-192; herein incorporated by reference.
inhibitor in a cell (e.g., cancerous cell) in which the Hh pathway is hyperactive or constitutively active, e.g. in a cell that comprises an activating mutation in a Smo gene or an inactivating mutation in a Ptch or SUFU gene, or a cell in which pathway activators such as SHH/IHH ligands, SMO or GLI1/2 are overexpressed. Other mutations that promote aberrant activation of the hedgehog signaling pathway are well known and can be readily determined by one of skill in the art. For a review of mutations associated with aberrant activation of hedgehog signaling, particularly mutations implicated in cancer, see, e.g., Pellegrini et al. (2017) Int. J.
Mol. Sci. 18(11) pii:
E2485, Bao et al. (2018) Mol. Nutr. Food Res. 62(1), Levanat et al. (2017) Curr. Pharm. Des.
23(1):73-94, Laukkanen et al. (2016) Anticancer Agents Med. Chem. 16(3):309-317, Suzman et al. (2015) Cancers (Basel). 7(4):1983-1993, Holikova et al. (2004) Int. J.
Dermatol.
43(12):865-869, Wetmore (2003) Curr. Opin. Genet. Dev. 13(1):34-42, Bale (2002) Annu.
Rev. Genomics Hum. Genet. 3:47-65, Lacour et al. (2002) Br. J. Dermatol. 146 Suppl 61:17-19, Wicking et al. (2001) Cancer Lett. 173(1):1-7, and Daya-Grosjean et al.
(2005) Cancer Lett. 225(2):181-192; herein incorporated by reference.
[0053] In performing the subject methods, the aPKC iota inhibitor alone or in combination with an HDAC inhibitor is provided to cells in an effective amount, that is, an amount that is effective to inhibit Hh pathway signaling. Biochemically speaking, an effective amount or effective dose of an aPKC iota inhibitor and/or an HDAC inhibitor is an amount sufficient to inhibit Hh pathway signaling in a cell by 30% or more, 40% or more, 50% or more, 60% or more, 70%
or more, 80% or more, 90% or more, 100% or more, 200% or more, or 500% or more. In other words, the activity of the Hh signaling pathway in a cell contacted with an effective amount or effective dose of an aPKC iota inhibitor or an HDAC inhibitor will be about 70% or less, about 60% or less, about 50% or less, about 40% or less, about 30% or less, about 20% or less, about 10%
or less, about 5% or less, or will be about 0%, i.e. negligible, the activity observed in a cell that has not been contacted with an effective amount/dose of an aPKC iota inhibitor and/or an HDAC inhibitor. Put another way, the Hh pathway signaling will be altered about 0.5-fold or more, 1-fold or more, 2-fold or more, 5-fold or more, 8-fold or more, or 10-fold or more.
or more, 80% or more, 90% or more, 100% or more, 200% or more, or 500% or more. In other words, the activity of the Hh signaling pathway in a cell contacted with an effective amount or effective dose of an aPKC iota inhibitor or an HDAC inhibitor will be about 70% or less, about 60% or less, about 50% or less, about 40% or less, about 30% or less, about 20% or less, about 10%
or less, about 5% or less, or will be about 0%, i.e. negligible, the activity observed in a cell that has not been contacted with an effective amount/dose of an aPKC iota inhibitor and/or an HDAC inhibitor. Put another way, the Hh pathway signaling will be altered about 0.5-fold or more, 1-fold or more, 2-fold or more, 5-fold or more, 8-fold or more, or 10-fold or more.
[0054] The amount of inhibition of a cell's activity by an aPKC iota inhibitor or an HDAC
inhibitor can be determined in a number of ways known to one of ordinary skill in the art of molecular biology. For example, the amount of the phosphorylated transcription factor Gli in a cell may be measured by Western blotting; the amount of binding of Gli to a DNA target sequence may be measured by an electrophoretic mobility assay (EMSA); the amount of expression of transcription factors that are normally activated by Hh signaling, e.g. ptch1, ptch2, hhip1, nhk2, and rab34, may be measured, for example, by measuring the RNA or protein levels of genes that are the transcriptional targets of Gli, or by transfecting/infecting the cell with a nucleic acid vector comprising a Gli-responsive promoter operably linked to a reporter protein such as luciferase, EGFP, etc. and qualitatively or quantitatively measuring the amount of reporter protein that is produced. In this way, the inhibitory effect of the aPKC
iota inhibitor or HDAC inhibitor may be confirmed.
inhibitor can be determined in a number of ways known to one of ordinary skill in the art of molecular biology. For example, the amount of the phosphorylated transcription factor Gli in a cell may be measured by Western blotting; the amount of binding of Gli to a DNA target sequence may be measured by an electrophoretic mobility assay (EMSA); the amount of expression of transcription factors that are normally activated by Hh signaling, e.g. ptch1, ptch2, hhip1, nhk2, and rab34, may be measured, for example, by measuring the RNA or protein levels of genes that are the transcriptional targets of Gli, or by transfecting/infecting the cell with a nucleic acid vector comprising a Gli-responsive promoter operably linked to a reporter protein such as luciferase, EGFP, etc. and qualitatively or quantitatively measuring the amount of reporter protein that is produced. In this way, the inhibitory effect of the aPKC
iota inhibitor or HDAC inhibitor may be confirmed.
[0055] In a clinical sense, an effective dose of an aPKC iota inhibitor or an HDAC
inhibitor is the dose that, when administered for a suitable period of time, usually at least about one week, and maybe about two weeks, or more, up to a period of about 4 weeks, 8 weeks, or longer will evidence an alteration the symptoms associated with undesired activity of the Hh signaling pathway. For example, an effective dose of an aPKC iota inhibitor or an HDAC
inhibitor is the dose that when administered for a suitable period of time, usually at least about one week, and may be about two weeks, or more, up to a period of about 4 weeks, 8 weeks, or longer will slow, halt or reverse tumor growth and metastasis in a patient suffering from cancer. It will be understood by those of skill in the art that an initial dose may be administered for such periods of time, followed by maintenance doses, which, in some cases, will be at a reduced dosage.
inhibitor is the dose that, when administered for a suitable period of time, usually at least about one week, and maybe about two weeks, or more, up to a period of about 4 weeks, 8 weeks, or longer will evidence an alteration the symptoms associated with undesired activity of the Hh signaling pathway. For example, an effective dose of an aPKC iota inhibitor or an HDAC
inhibitor is the dose that when administered for a suitable period of time, usually at least about one week, and may be about two weeks, or more, up to a period of about 4 weeks, 8 weeks, or longer will slow, halt or reverse tumor growth and metastasis in a patient suffering from cancer. It will be understood by those of skill in the art that an initial dose may be administered for such periods of time, followed by maintenance doses, which, in some cases, will be at a reduced dosage.
[0056]
Calculating the effective amount or effective dose of an aPKC iota inhibitor or an HDAC
inhibitor to be administered is within the skill of one of ordinary skill in the art, and will be routine to those persons skilled in the art. Needless to say, the final amount to be administered will be dependent upon a variety of factors, include the route of administration, the nature of the disorder or condition that is to be treated, and factors that will differ from patient to patient.
A competent clinician will be able to determine an effective amount of a therapeutic agent to administer to a patient to halt or reverse the progression the disease condition as required.
Utilizing LD50 animal data, and other information available for the agent, a clinician can determine the maximum safe dose for an individual, depending on the route of administration.
For instance, an intravenously administered dose may be more than an intrathecally or topically administered dose, given the greater body of fluid into which the therapeutic composition is being administered. Similarly, compositions which are rapidly cleared from the body may be administered at higher doses, or in repeated doses, in order to maintain a therapeutic concentration. Utilizing ordinary skill, the competent clinician will be able to optimize the dosage of a particular therapeutic in the course of routine clinical trials.
Calculating the effective amount or effective dose of an aPKC iota inhibitor or an HDAC
inhibitor to be administered is within the skill of one of ordinary skill in the art, and will be routine to those persons skilled in the art. Needless to say, the final amount to be administered will be dependent upon a variety of factors, include the route of administration, the nature of the disorder or condition that is to be treated, and factors that will differ from patient to patient.
A competent clinician will be able to determine an effective amount of a therapeutic agent to administer to a patient to halt or reverse the progression the disease condition as required.
Utilizing LD50 animal data, and other information available for the agent, a clinician can determine the maximum safe dose for an individual, depending on the route of administration.
For instance, an intravenously administered dose may be more than an intrathecally or topically administered dose, given the greater body of fluid into which the therapeutic composition is being administered. Similarly, compositions which are rapidly cleared from the body may be administered at higher doses, or in repeated doses, in order to maintain a therapeutic concentration. Utilizing ordinary skill, the competent clinician will be able to optimize the dosage of a particular therapeutic in the course of routine clinical trials.
[0057] The subject methods may be used to inhibit Hh pathway signaling -- and hence cellular activities associated with Hh pathway signaling -- in cells in vitro and in vivo. For example, any cell in which Hh pathway signaling is undesirable, e.g. a cancerous cell in which uncontrolled Hh pathway signaling promotes proliferation or metastasis, may be contacted with an aPKC iota inhibitor and/or an HDAC inhibitor. Cells may be from any mammalian species, e.g. murine, rodent, canine, feline, equine, bovine, ovine, primate, human, etc.
[0058] If the subject methods are performed in vitro, cells may be from established cell lines or they may be primary cells, where "primary cells", "primary cell lines", and "primary cultures"
are used interchangeably herein to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, i.e. splittings, of the culture. For example, primary cultures are cultures that may have been passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times to go through the crisis stage. Typically, the primary cell lines of the present invention are maintained for fewer than 10 passages in vitro.
are used interchangeably herein to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, i.e. splittings, of the culture. For example, primary cultures are cultures that may have been passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times to go through the crisis stage. Typically, the primary cell lines of the present invention are maintained for fewer than 10 passages in vitro.
[0059] If the cells are primary cells, they may be harvested from an individual by any convenient method. For example, cells, e.g. blood cells, e.g. leukocytes, may be harvested by apheresis, leukocytapheresis, density gradient separation, etc. As another example, cells, e.g. skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, nervous system tissue, etc. may be harvested by biopsy. An appropriate solution may be used for dispersion or suspension of the harvested cells. Such solution will generally be a balanced salt solution, e.g. normal saline, PBS, Hank's balanced salt solution, etc., conveniently supplemented with fetal calf serum or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, generally from 5-25 mM. Convenient buffers include HEPES, phosphate buffers, lactate buffers, etc. The cells may be used immediately, or they may be stored, frozen, for long periods of time, being thawed and capable of being reused. In such cases, the cells will usually be frozen in 10% DMSO, 50% serum, 40%
buffered medium, or some other such solution as is commonly used in the art to preserve cells at such freezing temperatures, and thawed in a manner as commonly known in the art for thawing frozen cultured cells.
buffered medium, or some other such solution as is commonly used in the art to preserve cells at such freezing temperatures, and thawed in a manner as commonly known in the art for thawing frozen cultured cells.
[0060] The aPKC iota inhibitor or HDAC inhibitor may be dissolved in water or alcohols or solvents such as DMSO or DMF, and diluted into water or an appropriate buffer prior to being provided to cells.
[0061] To modulate Hh pathway signaling, the aPKC iota inhibitor or HDAC inhibitor may be provided to the cells for about 30 minutes to about 24 hours, e.g., 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, or any other period from about 30 minutes to about 24 hours, which may be repeated with a frequency of about every day to about every 4 days, e.g., every 1.5 days, every 2 days, every 3 days, or any other frequency from about every day to about every four days. The agent may be provided to the subject cells one or more times, e.g.
one time, twice, three times, or more than three times, and the cells allowed to incubate with the agent for some amount of time following each contacting event e.g. 16-24 hours, after which time the media is replaced with fresh media and the cells are cultured further.
one time, twice, three times, or more than three times, and the cells allowed to incubate with the agent for some amount of time following each contacting event e.g. 16-24 hours, after which time the media is replaced with fresh media and the cells are cultured further.
[0062]
Contacting the cells with the aPKC iota inhibitor or HDAC inhibitor may occur in any culture media and under any culture conditions that promote the survival of the cells. For example, cells may be suspended in any appropriate nutrient medium that is convenient, such as Iscove's modified DMEM or RPM! 1640, supplemented with fetal calf serum or heat inactivated goat serum (about 5-10%), L-glutamine, a thiol, particularly 2-mercaptoethanol, and antibiotics, e.g. penicillin and streptomycin. The culture may contain growth factors to which the cells are responsive. Growth factors, as defined herein, are molecules capable of promoting survival, growth and/or differentiation of cells, either in culture or in the intact tissue, through specific effects on a transmembrane receptor. Growth factors include polypeptides and non-polypeptide factors. Conditions that promote the survival of cells are typically permissive of nonhomologous end joining and homologous recombination.
Contacting the cells with the aPKC iota inhibitor or HDAC inhibitor may occur in any culture media and under any culture conditions that promote the survival of the cells. For example, cells may be suspended in any appropriate nutrient medium that is convenient, such as Iscove's modified DMEM or RPM! 1640, supplemented with fetal calf serum or heat inactivated goat serum (about 5-10%), L-glutamine, a thiol, particularly 2-mercaptoethanol, and antibiotics, e.g. penicillin and streptomycin. The culture may contain growth factors to which the cells are responsive. Growth factors, as defined herein, are molecules capable of promoting survival, growth and/or differentiation of cells, either in culture or in the intact tissue, through specific effects on a transmembrane receptor. Growth factors include polypeptides and non-polypeptide factors. Conditions that promote the survival of cells are typically permissive of nonhomologous end joining and homologous recombination.
[0063]
Cancerous cells of interest for study and treatment in the present application include precancerous (e.g., benign), malignant, pre-metastatic, metastatic, and non-metastatic cells, where the cancerous phenotype is promoted by Hh pathway signaling. In other words, Hh pathway signaling (and in many instances, unregulated Hh pathway signaling) predisposes cells in the individual to become cancerous, or induces or enhances the symptoms of cancer in the individual, for example tumor growth and metastasis. In many such instances, Hh pathway signaling is elevated in tumor cells relative to the level of signaling observed in a healthy cell, e.g. 2-fold or more, 3-fold or more, 4-fold or more, 6-fold or more, 8-fold or more, 10-fold or more, 20-fold or more, or 50-fold or more over the amount of Hh pathway signaling in a healthy cell. The level of Hh signaling may be measured by any convenient method, e.g.
as known in the art or as described herein.
Cancerous cells of interest for study and treatment in the present application include precancerous (e.g., benign), malignant, pre-metastatic, metastatic, and non-metastatic cells, where the cancerous phenotype is promoted by Hh pathway signaling. In other words, Hh pathway signaling (and in many instances, unregulated Hh pathway signaling) predisposes cells in the individual to become cancerous, or induces or enhances the symptoms of cancer in the individual, for example tumor growth and metastasis. In many such instances, Hh pathway signaling is elevated in tumor cells relative to the level of signaling observed in a healthy cell, e.g. 2-fold or more, 3-fold or more, 4-fold or more, 6-fold or more, 8-fold or more, 10-fold or more, 20-fold or more, or 50-fold or more over the amount of Hh pathway signaling in a healthy cell. The level of Hh signaling may be measured by any convenient method, e.g.
as known in the art or as described herein.
[0064] In some applications, the aPKC iota inhibitor or HDAC inhibitor is employed to modulate Hh pathway signaling in vivo, e.g. to inhibit tumor growth or metastasis to treat cancer. In these in vivo embodiments, the aPKC iota inhibitor or HDAC
inhibitor is administered directly to the individual. An aPKC iota modulator may be administered by any of a number of well-known methods in the art as described below.
Formulations
inhibitor is administered directly to the individual. An aPKC iota modulator may be administered by any of a number of well-known methods in the art as described below.
Formulations
[0065] The aPKC iota inhibitors (e.g., 0RT0422839 or 0RT0364436) or HDAC inhibitors can be incorporated into a variety of formulations. More particularly, the aPKC
iota inhibitors or HDAC inhibitors may be formulated into pharmaceutical compositions by combination with appropriate pharmaceutically acceptable carriers or diluents. Pharmaceutical preparations are compositions that include one or more aPKC iota inhibitors and/or HDAC
inhibitors in a pharmaceutically acceptable vehicle. "Pharmaceutically acceptable vehicles"
may be vehicles approved by a regulatory agency of the Federal or a state government or listed in the U.S.
Pharmacopeia or other generally recognized pharmacopeia for use in mammals, such as humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is formulated for administration to a mammal. Such pharmaceutical vehicles can be lipids, e.g. liposomes, e.g. liposome dendrimers; liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, saline; gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. Pharmaceutical compositions may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. As such, administration of the aPKC iota inhibitor and/or HDAC
inhibitor can be achieved in various ways, including transdermal, intradermal, oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intracheal, etc., administration. The active agent may be systemic after administration or may be localized by the use of regional administration, intramural administration, or use of an implant that acts to retain the active dose at the site of implantation. The active agent may be formulated for immediate activity or it may be formulated for sustained release.
iota inhibitors or HDAC inhibitors may be formulated into pharmaceutical compositions by combination with appropriate pharmaceutically acceptable carriers or diluents. Pharmaceutical preparations are compositions that include one or more aPKC iota inhibitors and/or HDAC
inhibitors in a pharmaceutically acceptable vehicle. "Pharmaceutically acceptable vehicles"
may be vehicles approved by a regulatory agency of the Federal or a state government or listed in the U.S.
Pharmacopeia or other generally recognized pharmacopeia for use in mammals, such as humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is formulated for administration to a mammal. Such pharmaceutical vehicles can be lipids, e.g. liposomes, e.g. liposome dendrimers; liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, saline; gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. Pharmaceutical compositions may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. As such, administration of the aPKC iota inhibitor and/or HDAC
inhibitor can be achieved in various ways, including transdermal, intradermal, oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intracheal, etc., administration. The active agent may be systemic after administration or may be localized by the use of regional administration, intramural administration, or use of an implant that acts to retain the active dose at the site of implantation. The active agent may be formulated for immediate activity or it may be formulated for sustained release.
[0066] For some conditions, particularly central nervous system conditions, it may be necessary to formulate agents to cross the blood-brain barrier (BBB). One strategy for drug delivery through the blood-brain barrier (BBB) entails disruption of the BBB, either by osmotic means such as mannitol or leukotrienes, or biochemically by the use of vasoactive substances such as bradykinin. The potential for using BBB opening to target specific agents to brain tumors is also an option. A BBB disrupting agent can be co-administered with the therapeutic compositions of the invention when the compositions are administered by intravascular injection. Other strategies to go through the BBB may entail the use of endogenous transport systems, including Caveolin-1 mediated transcytosis, carrier-mediated transporters such as glucose and amino acid carriers, receptor-mediated transcytosis for insulin or transferrin, and active efflux transporters such as p-glycoprotein. Active transport moieties may also be conjugated to the therapeutic compounds for use in the invention to facilitate transport across the endothelial wall of the blood vessel. Alternatively, drug delivery of therapeutics agents behind the BBB may be by local delivery, for example by intrathecal delivery, e.g. through an Ommaya reservoir (see e.g. US Patent Nos. 5,222,982 and 5385582, incorporated herein by reference); by bolus injection, e.g. by a syringe, e.g. intravitreally or intracranially; by continuous infusion, e.g. by cannulation, e.g. with convection (see e.g. US
Application No.
20070254842, incorporated here by reference); or by implanting a device upon which the agent has been reversibly affixed (see e.g. US Application Nos. 20080081064 and 20090196903, incorporated herein by reference).
Application No.
20070254842, incorporated here by reference); or by implanting a device upon which the agent has been reversibly affixed (see e.g. US Application Nos. 20080081064 and 20090196903, incorporated herein by reference).
[0067] For inclusion in a medicament, the aPKC iota inhibitor and/or HDAC inhibitor may be obtained from a suitable commercial source. As a general proposition, the total pharmaceutically effective amount of the aPKC iota inhibitor and/or HDAC
inhibitor administered parenterally per dose will be in a range that can be measured by a dose response curve.
inhibitor administered parenterally per dose will be in a range that can be measured by a dose response curve.
[0068] For aPKC iota inhibitor-based therapies with or without an HDAC inhibitor, i.e.
preparations to be used for therapeutic administration, may be sterile.
Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 j.im membranes).
Therapeutic compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The compositions comprising an aPKC iota inhibitor and/or HDAC inhibitor may be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-mL vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous solution of compound, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized compound using bacteriostatic Water-for-Injection.
Alternatively, the aPKC iota inhibitor and/or HDAC inhibitor may be formulated into lotions for topical administration.
preparations to be used for therapeutic administration, may be sterile.
Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 j.im membranes).
Therapeutic compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The compositions comprising an aPKC iota inhibitor and/or HDAC inhibitor may be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-mL vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous solution of compound, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized compound using bacteriostatic Water-for-Injection.
Alternatively, the aPKC iota inhibitor and/or HDAC inhibitor may be formulated into lotions for topical administration.
[0069]
Pharmaceutical compositions can include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers of diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration.
The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, buffered water, physiological saline, PBS, Ringer's solution, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation can include other carriers, adjuvants, or non-toxic, nontherapeutic, nonimmunogenic stabilizers, excipients and the like. The compositions can also include additional substances to approximate physiological conditions, such as pH
adjusting and buffering agents, toxicity adjusting agents, wetting agents and detergents.
Pharmaceutical compositions can include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers of diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration.
The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, buffered water, physiological saline, PBS, Ringer's solution, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation can include other carriers, adjuvants, or non-toxic, nontherapeutic, nonimmunogenic stabilizers, excipients and the like. The compositions can also include additional substances to approximate physiological conditions, such as pH
adjusting and buffering agents, toxicity adjusting agents, wetting agents and detergents.
[0070] The composition can also include any of a variety of stabilizing agents, such as an antioxidant for example. When the pharmaceutical composition includes a polypeptide, the polypeptide can be complexed with various well-known compounds that enhance the in vivo stability of the polypeptide, or otherwise enhance its pharmacological properties (e.g., increase the half-life of the polypeptide, reduce its toxicity, enhance solubility or uptake).
Examples of such modifications or complexing agents include sulfate, gluconate, citrate and phosphate. The nucleic acids or polypeptides of a composition can also be complexed with molecules that enhance their in vivo attributes. Such molecules include, for example, carbohydrates, polyamines, amino acids, other peptides, ions (e.g., sodium, potassium, calcium, magnesium, manganese), and lipids.
Examples of such modifications or complexing agents include sulfate, gluconate, citrate and phosphate. The nucleic acids or polypeptides of a composition can also be complexed with molecules that enhance their in vivo attributes. Such molecules include, for example, carbohydrates, polyamines, amino acids, other peptides, ions (e.g., sodium, potassium, calcium, magnesium, manganese), and lipids.
[0071]
Further guidance regarding formulations that are suitable for various types of administration can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985). For a brief review of methods for drug delivery, see, Langer, Science 249:1527-1533 (1990).
Further guidance regarding formulations that are suitable for various types of administration can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985). For a brief review of methods for drug delivery, see, Langer, Science 249:1527-1533 (1990).
[0072] The pharmaceutical compositions can be administered for prophylactic and/or therapeutic treatments. Toxicity and therapeutic efficacy of the active ingredient can be determined according to standard pharmaceutical procedures in cell cultures and/or experimental animals, including, for example, determining the LD50 (the dose lethal to 50%
of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Therapies that exhibit large therapeutic indices are preferred.
of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Therapies that exhibit large therapeutic indices are preferred.
[0073] The data obtained from cell culture and/or animal studies can be used in formulating a range of dosages for humans. The dosage of the active ingredient typically lines within a range of circulating concentrations that include the ED50 with low toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
[0074] The components used to formulate the pharmaceutical compositions are preferably of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food (NF) grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Moreover, compositions intended for in vivo use are usually sterile. To the extent that a given compound must be synthesized prior to use, the resulting product is typically substantially free of any potentially toxic agents, particularly any endotoxins, which may be present during the synthesis or purification process. Compositions for parental administration are also sterile, substantially isotonic and made under GMP
conditions.
conditions.
[0075] The aPKC iota inhibitor and/or HDAC inhibitor may be provided in addition to other agents. For example, in methods of treating cancer that is promoted by Hh pathway signaling, an aPKC iota inhibitor and/or HDAC inhibitor may be coadministered with other known cancer therapies.
Administration
Administration
[0076]
Hedgehog pathway-dependent cancers that may be treated according to the methods described herein include any cancer dependent on activation of the hedgehog pathway or associated with aberrant activation or constitutive activation of the Hedgehog pathway such as, but not limited to, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, small cell lung cancer, retinoblastoma, gastric and upper gastrointestinal track cancer, osteosarcoma, pancreatic cancer, breast cancer, colon cancer, ovarian cancer, brain cancer, mammary gland cancer, thyroid cancer, and prostate cancer.
Hedgehog pathway-dependent cancers that may be treated according to the methods described herein include any cancer dependent on activation of the hedgehog pathway or associated with aberrant activation or constitutive activation of the Hedgehog pathway such as, but not limited to, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, small cell lung cancer, retinoblastoma, gastric and upper gastrointestinal track cancer, osteosarcoma, pancreatic cancer, breast cancer, colon cancer, ovarian cancer, brain cancer, mammary gland cancer, thyroid cancer, and prostate cancer.
[0077] At least one therapeutically effective dose of an aPKC iota inhibitor (e.g., or CRT0364436) either alone or in combination with an HDAC inhibitor, and/or optionally other anti-cancer agents will be administered. By "therapeutically effective dose or amount" of each of these agents is intended an amount that when administered brings about a positive therapeutic response with respect to treatment of an individual for a hedgehog pathway-dependent cancer. Of particular interest is an amount of these agents that provides an anti-tumor effect, as defined herein. By "positive therapeutic response" is intended the individual undergoing the treatment according to the invention exhibits an improvement in one or more symptoms of the hedgehog pathway-dependent cancer for which the individual is undergoing therapy.
[0078] Thus, for example, a "positive therapeutic response" would be an improvement in the disease in association with the therapy (e.g., therapy with an aPKC iota inhibitor or combination therapy with an aPKC iota inhibitor and an HDAC inhibitor and/or optionally other anti-cancer agents), and/or an improvement in one or more symptoms of the disease in association with the therapy. Therefore, for example, a positive therapeutic response would refer to one or more of the following improvements in the disease: (1) reduction in tumor size;
(2) reduction in the number of cancer cells; (3) inhibition (i.e., slowing to some extent, preferably halting) of tumor growth; (4) inhibition (i.e., slowing to some extent, preferably halting) of cancer cell infiltration into peripheral organs; (5) inhibition (i.e., slowing to some extent, preferably halting) of tumor metastasis; and (6) some extent of relief from one or more symptoms associated with the cancer.
(2) reduction in the number of cancer cells; (3) inhibition (i.e., slowing to some extent, preferably halting) of tumor growth; (4) inhibition (i.e., slowing to some extent, preferably halting) of cancer cell infiltration into peripheral organs; (5) inhibition (i.e., slowing to some extent, preferably halting) of tumor metastasis; and (6) some extent of relief from one or more symptoms associated with the cancer.
[0079] Such therapeutic responses may be further characterized as to degree of improvement. Thus, for example, an improvement may be characterized as a complete response. By "complete response" is documentation of the disappearance of all symptoms and signs of all measurable or evaluable disease confirmed by physical examination, laboratory, nuclear and radiographic studies (i.e., CT (computer tomography) and/or MRI
(magnetic resonance imaging)), and other non-invasive procedures repeated for all initial abnormalities or sites positive at the time of entry into the study.
Alternatively, an improvement in the disease may be categorized as being a partial response. By "partial response" is intended a reduction of greater than 50% in the sum of the products of the perpendicular diameters of all measurable lesions when compared with pretreatment measurements (for patients with evaluable response only, partial response does not apply).
(magnetic resonance imaging)), and other non-invasive procedures repeated for all initial abnormalities or sites positive at the time of entry into the study.
Alternatively, an improvement in the disease may be categorized as being a partial response. By "partial response" is intended a reduction of greater than 50% in the sum of the products of the perpendicular diameters of all measurable lesions when compared with pretreatment measurements (for patients with evaluable response only, partial response does not apply).
[0080] In certain embodiments, multiple therapeutically effective doses of the aPKC iota inhibitor either alone or in combination with an HDAC inhibitor, and optionally other anti-cancer agents will be administered according to a daily dosing regimen, or intermittently. For example, a therapeutically effective dose can be administered, one day a week, two days a week, three days a week, four days a week, or five days a week, and so forth.
By "intermittent"
administration is intended the therapeutically effective dose can be administered, for example, every other day, every two days, every three days, and so forth. For example, in some embodiments, the aPKC iota inhibitor either alone or in combination with an HDAC inhibitor, and/or optionally other anti-cancer agents will be administered twice-weekly or thrice-weekly for an extended period of time, such as for 1, 2, 3, 4, 5, 6, 7, 8...10...15...24 weeks, and so forth. By "twice-weekly" or "two times per week" is intended that two therapeutically effective doses of the agent in question is administered to the subject within a 7 day period, beginning on day 1 of the first week of administration, with a minimum of 72 hours, between doses and a maximum of 96 hours between doses. By "thrice weekly" or "three times per week" is intended that three therapeutically effective doses are administered to the subject within a 7 day period, allowing for a minimum of 48 hours between doses and a maximum of 72 hours between doses. For purposes of the present invention, this type of dosing is referred to as "intermittent" therapy. In accordance with the methods of the present invention, a subject can receive intermittent therapy (i.e., twice-weekly or thrice-weekly administration of a therapeutically effective dose) for one or more weekly cycles until the desired therapeutic response is achieved. The agents can be administered by any acceptable route of administration as noted herein below.
By "intermittent"
administration is intended the therapeutically effective dose can be administered, for example, every other day, every two days, every three days, and so forth. For example, in some embodiments, the aPKC iota inhibitor either alone or in combination with an HDAC inhibitor, and/or optionally other anti-cancer agents will be administered twice-weekly or thrice-weekly for an extended period of time, such as for 1, 2, 3, 4, 5, 6, 7, 8...10...15...24 weeks, and so forth. By "twice-weekly" or "two times per week" is intended that two therapeutically effective doses of the agent in question is administered to the subject within a 7 day period, beginning on day 1 of the first week of administration, with a minimum of 72 hours, between doses and a maximum of 96 hours between doses. By "thrice weekly" or "three times per week" is intended that three therapeutically effective doses are administered to the subject within a 7 day period, allowing for a minimum of 48 hours between doses and a maximum of 72 hours between doses. For purposes of the present invention, this type of dosing is referred to as "intermittent" therapy. In accordance with the methods of the present invention, a subject can receive intermittent therapy (i.e., twice-weekly or thrice-weekly administration of a therapeutically effective dose) for one or more weekly cycles until the desired therapeutic response is achieved. The agents can be administered by any acceptable route of administration as noted herein below.
[0081] In certain embodiments, combination therapy with an aPKC iota inhibitor and an HDAC
inhibitor, and optionally other anti-cancer agents is administered. The aPKC
iota inhibitor can be administered prior to, concurrent with, or subsequent to the HDAC
inhibitor. If provided at the same time as the HDAC inhibitor, the aPKC iota inhibitor can be provided in the same or in a different composition. Thus, the two agents can be presented to the individual by way of concurrent therapy. By "concurrent therapy" is intended administration to a human subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy. For example, concurrent therapy may be achieved by administering at least one therapeutically effective dose of a pharmaceutical composition comprising an aPKC
iota inhibitor and at least one therapeutically effective dose of a pharmaceutical composition comprising at least one an HDAC inhibitor according to a particular dosing regimen. Similarly, the aPKC iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents, can be administered in at least one therapeutic dose. Administration of the separate pharmaceutical compositions can be at the same time (i.e., simultaneously) or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
inhibitor, and optionally other anti-cancer agents is administered. The aPKC
iota inhibitor can be administered prior to, concurrent with, or subsequent to the HDAC
inhibitor. If provided at the same time as the HDAC inhibitor, the aPKC iota inhibitor can be provided in the same or in a different composition. Thus, the two agents can be presented to the individual by way of concurrent therapy. By "concurrent therapy" is intended administration to a human subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy. For example, concurrent therapy may be achieved by administering at least one therapeutically effective dose of a pharmaceutical composition comprising an aPKC
iota inhibitor and at least one therapeutically effective dose of a pharmaceutical composition comprising at least one an HDAC inhibitor according to a particular dosing regimen. Similarly, the aPKC iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents, can be administered in at least one therapeutic dose. Administration of the separate pharmaceutical compositions can be at the same time (i.e., simultaneously) or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
[0082] In certain embodiments, the aPKC iota inhibitor is administered for a brief period prior to administration of the HDAC inhibitor and continued for a brief period after treatment with the HDAC inhibitor is discontinued in order to ensure that levels of the aPKC
iota inhibitor are adequate in the subject during therapy to inhibit association of GUI and HDAC1 and activation of GLI1 and the hedgehog signaling pathway. For example, the aPKC iota inhibitor can be administered starting one week before administration of the first dose of the HDAC inhibitor and continued for one week after administration of the last dose of the HDAC
inhibitor to the subject.
iota inhibitor are adequate in the subject during therapy to inhibit association of GUI and HDAC1 and activation of GLI1 and the hedgehog signaling pathway. For example, the aPKC iota inhibitor can be administered starting one week before administration of the first dose of the HDAC inhibitor and continued for one week after administration of the last dose of the HDAC
inhibitor to the subject.
[0083] In other embodiments, the pharmaceutical compositions comprising the agents, such as the aPKC iota inhibitor and/or HDAC inhibitor and/or optionally other anti-cancer agents, is a sustained-release formulation, or a formulation that is administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non-sustained-release pharmaceutical composition.
[0084] The pharmaceutical compositions comprising the aPKC iota inhibitor and/or HDAC
inhibitor and optionally other anti-cancer agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art. Suitable routes of administration include parenteral administration, such as subcutaneous (SC), intraperitoneal (IP), intramuscular (IM), intravenous (IV), or infusion, oral, pulmonary, nasal, topical, transdermal, intratumoral, and suppositories. Where the composition is administered via pulmonary delivery, the therapeutically effective dose is adjusted such that the soluble level of the agent, such as the aPKC iota inhibitor and/or HDAC
inhibitor in the bloodstream, is equivalent to that obtained with a therapeutically effective dose that is administered parenterally, for example SC, IP, IM, or IV. In some embodiments, pharmaceutical compositions comprising the aPKC iota inhibitor and/or HDAC
inhibitor and optionally other anti-cancer agents are administered by IM or SC injection, particularly by IM
or SC injection locally to a tumor. In some embodiments, the aPKC iota inhibitor and/or HDAC
inhibitor and optionally other anti-cancer agents are administered topically such as on a patch or in a gel.
inhibitor and optionally other anti-cancer agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art. Suitable routes of administration include parenteral administration, such as subcutaneous (SC), intraperitoneal (IP), intramuscular (IM), intravenous (IV), or infusion, oral, pulmonary, nasal, topical, transdermal, intratumoral, and suppositories. Where the composition is administered via pulmonary delivery, the therapeutically effective dose is adjusted such that the soluble level of the agent, such as the aPKC iota inhibitor and/or HDAC
inhibitor in the bloodstream, is equivalent to that obtained with a therapeutically effective dose that is administered parenterally, for example SC, IP, IM, or IV. In some embodiments, pharmaceutical compositions comprising the aPKC iota inhibitor and/or HDAC
inhibitor and optionally other anti-cancer agents are administered by IM or SC injection, particularly by IM
or SC injection locally to a tumor. In some embodiments, the aPKC iota inhibitor and/or HDAC
inhibitor and optionally other anti-cancer agents are administered topically such as on a patch or in a gel.
[0085] In some embodiments, the aPKC iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents are administered by infusion or by local injection, e.g. by infusion at a rate of about 50 mg/h to about 400 mg/h, including about 75 mg/h to about 375 mg/h, about 100 mg/h to about 350 mg/h, about 150 mg/h to about 350 mg/h, about 200 mg/h to about 300 mg/h, about 225 mg/h to about 275 mg/h. Exemplary rates of infusion can achieve a desired therapeutic dose of, for example, about 0.5 mg/m2/day to about 10 mg/m2/day, including about 1 mg/m2/day to about 9 mg/m2/day, about 2 mg/m2/day to about 8 mg/m2/day, about 3 mg/m2/day to about 7 mg/m2/day, about 4 mg/m2/day to about 6 mg/m2/day, about 4.5 mg/m2/day to about 5.5 mg/m2/day. Administration (e.g., by infusion) can be repeated over a desired period, e.g., repeated over a period of about 1 day to about 5 days or once every several days, for example, about five days, over about 1 month, about 2 months, etc. The aPKC iota inhibitor and/or HDAC inhibitor also can be administered prior, at the time of, or after other therapeutic interventions, such as surgical intervention to remove cancerous cells.
The aPKC iota inhibitor and/or HDAC inhibitor can also be administered as part of a combination therapy, in which at least one of immunotherapy, chemotherapy, radiation therapy, or biologic therapy is administered to the subject.
The aPKC iota inhibitor and/or HDAC inhibitor can also be administered as part of a combination therapy, in which at least one of immunotherapy, chemotherapy, radiation therapy, or biologic therapy is administered to the subject.
[0086]
Factors influencing the respective amount of the various compositions to be administered include, but are not limited to, the mode of administration, the frequency of administration (i.e., daily, or intermittent administration, such as twice- or thrice-weekly), the particular disease undergoing therapy, the severity of the disease, the history of the disease, whether the individual is undergoing concurrent therapy with another therapeutic agent, and the age, height, weight, health, and physical condition of the individual undergoing therapy.
Generally, a higher dosage of this agent is preferred with increasing weight of the subject undergoing therapy.
Factors influencing the respective amount of the various compositions to be administered include, but are not limited to, the mode of administration, the frequency of administration (i.e., daily, or intermittent administration, such as twice- or thrice-weekly), the particular disease undergoing therapy, the severity of the disease, the history of the disease, whether the individual is undergoing concurrent therapy with another therapeutic agent, and the age, height, weight, health, and physical condition of the individual undergoing therapy.
Generally, a higher dosage of this agent is preferred with increasing weight of the subject undergoing therapy.
[0087]
Individual doses of the aPKC iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents are typically not less than an amount required to produce a measurable effect on the subject, and may be determined based on the pharmacokinetics and pharmacology for absorption, distribution, metabolism, and excretion ("ADME") of the aPKC
iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents and their by-products, and thus based on the disposition of the compositions within the subject. This includes consideration of the route of administration as well as dosage amount, which can be adjusted for topical (applied directly where action is desired for mainly a local effect), enteral (applied via digestive tract for systemic or local effects when retained in part of the digestive tract), or parenteral (applied by routes other than the digestive tract for systemic or local effects) applications. For instance, administration of the aPKC iota inhibitor (e.g., 0RT0422839 or 0RT0364436) may be topical or via injection, e.g. intravenous, intramuscular, or intratumoral injection or a combination thereof.
Individual doses of the aPKC iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents are typically not less than an amount required to produce a measurable effect on the subject, and may be determined based on the pharmacokinetics and pharmacology for absorption, distribution, metabolism, and excretion ("ADME") of the aPKC
iota inhibitor and/or HDAC inhibitor and optionally other anti-cancer agents and their by-products, and thus based on the disposition of the compositions within the subject. This includes consideration of the route of administration as well as dosage amount, which can be adjusted for topical (applied directly where action is desired for mainly a local effect), enteral (applied via digestive tract for systemic or local effects when retained in part of the digestive tract), or parenteral (applied by routes other than the digestive tract for systemic or local effects) applications. For instance, administration of the aPKC iota inhibitor (e.g., 0RT0422839 or 0RT0364436) may be topical or via injection, e.g. intravenous, intramuscular, or intratumoral injection or a combination thereof.
[0088]
Disposition of the aPKC iota inhibitor and its corresponding biological activity within a subject is typically gauged against the fraction of the aPKC iota inhibitor present at a target of interest. For example, an aPKC iota inhibitor once administered can accumulate with a glycoconjugate or other biological target that concentrates the material in cancer cells and cancerous tissue. Thus, dosing regimens in which the aPKC iota inhibitor is administered so as to accumulate in a target of interest over time can be part of a strategy to allow for lower individual doses. This can also mean that, for example, the dose of an aPKC
iota inhibitor that is cleared more slowly in vivo can be lowered relative to the effective concentration calculated from in vitro assays (e.g., effective amount in vitro approximates mM
concentration, versus less than mM concentrations in vivo).
Disposition of the aPKC iota inhibitor and its corresponding biological activity within a subject is typically gauged against the fraction of the aPKC iota inhibitor present at a target of interest. For example, an aPKC iota inhibitor once administered can accumulate with a glycoconjugate or other biological target that concentrates the material in cancer cells and cancerous tissue. Thus, dosing regimens in which the aPKC iota inhibitor is administered so as to accumulate in a target of interest over time can be part of a strategy to allow for lower individual doses. This can also mean that, for example, the dose of an aPKC
iota inhibitor that is cleared more slowly in vivo can be lowered relative to the effective concentration calculated from in vitro assays (e.g., effective amount in vitro approximates mM
concentration, versus less than mM concentrations in vivo).
[0089] As an example, the effective amount of a dose or dosing regimen can be gauged from the 1050 of a given aPKC iota inhibitor for inhibiting aPKC kinase activity and/or GUI activation, and/or activation of the hedgehog pathway and/or cell proliferation and/or cell migration/invasion. By "IC5o" is intended the concentration of a drug required for 50% inhibition in vitro. Alternatively, the effective amount can be gauged from the E050 of a given aPKC iota inhibitor concentration. By "E050" is intended the plasma concentration required for obtaining 50% of a maximum effect in vivo. In related embodiments, dosage may also be determined based on ED50 (effective dosage).
[0090] In general, an effective amount is usually not more than 200X the calculated IC5o.
Typically, the amount of an aPKC iota inhibitor that is administered is less than about 200X, less than about 150X, less than about 100X and many embodiments less than about 75X, less than about 60X, 50X, 45X, 40X, 35X, 30X, 25X, 20X, 15X, 10X and even less than about 8X or 2X than the calculated 1050. In one embodiment, the effective amount is about 1X to 50X
of the calculated 1050, and sometimes about 2X to 40X, about 3X to 30X or about 4X to 20X
of the calculated 1050. In other embodiments, the effective amount is the same as the calculated 1050, and in certain embodiments the effective amount is an amount that is more than the calculated 1050.
Typically, the amount of an aPKC iota inhibitor that is administered is less than about 200X, less than about 150X, less than about 100X and many embodiments less than about 75X, less than about 60X, 50X, 45X, 40X, 35X, 30X, 25X, 20X, 15X, 10X and even less than about 8X or 2X than the calculated 1050. In one embodiment, the effective amount is about 1X to 50X
of the calculated 1050, and sometimes about 2X to 40X, about 3X to 30X or about 4X to 20X
of the calculated 1050. In other embodiments, the effective amount is the same as the calculated 1050, and in certain embodiments the effective amount is an amount that is more than the calculated 1050.
[0091] An effect amount will typically not be more than 100X the calculated E050. For instance, the amount of an aPKC iota inhibitor that is administered is less than about 100X, less than about 50X, less than about 40X, 35X, 30X, or 25X and many embodiments less than about 20X, less than about 15X and even less than about 10X, 9X, 9X, 7X, 6X, 5X, 4X, 3X, 2X or 1X than the calculated E050. The effective amount may be about 1X to 30X of the calculated E050, and sometimes about 1X to 20X, or about 1X to 10X of the calculated E050. The effective amount may also be the same as the calculated E050 or more than the calculated E050. The IC50 can be calculated by inhibiting aPKC kinase activity and/or GLI1 activation, and/or cell proliferation and/or cell migration/invasion in vitro.
[0092] In order to achieve efficacy, the level of the aPKC iota inhibitor must be above a specific level for a specific time. Efficacy is dose dependent and higher levels of the aPKC iota inhibitor contribute to greater anti-tumor effects. In order to minimize toxicity, the level of the aPKC iota inhibitor may be maintained below a certain level within a specific time and for a specific time (a "rest period" allows clearance of the aPKC iota inhibitor). That is, the drug is kept below a certain level by a certain time before the next dose is given. Shorter rests between doses contribute to greater toxicity.
[0093] In certain embodiments, the method of treatment of a patient having a hedgehog pathway-dependent cancer comprises a treatment cycle with an aPKC iota inhibitor either alone or in combination with an HDAC inhibitor, and/or optionally other anti-cancer agents followed by a rest period in which no aPKC iota inhibitor and/or HDAC
inhibitor is administered to allow the patient to "recover" from the undesirable effects of the aPKC
iota inhibitor and/or HDAC inhibitor. Multiple doses of an aPKC iota inhibitor and/or HDAC inhibitor can be administered according to a daily dosing regimen or intermittently, followed by a rest period.
inhibitor is administered to allow the patient to "recover" from the undesirable effects of the aPKC
iota inhibitor and/or HDAC inhibitor. Multiple doses of an aPKC iota inhibitor and/or HDAC inhibitor can be administered according to a daily dosing regimen or intermittently, followed by a rest period.
[0094] Where a subject undergoing therapy in accordance with the previously mentioned dosing regimens exhibits a partial response, or a relapse following a prolonged period of remission, subsequent courses of therapy may be needed to achieve complete remission of the disease. Thus, subsequent to a period of time off from a first treatment period, a subject may receive one or more additional treatment periods comprising administration of an aPKC
iota inhibitor either alone or in combination with an HDAC inhibitor, and optionally other anti-cancer agents. Such a period of time off between treatment periods is referred to herein as a time period of discontinuance. It is recognized that the length of the time period of discontinuance is dependent upon the degree of tumor response (i.e., complete versus partial) achieved with any prior treatment periods of therapy with these therapeutic agents.
Applications
iota inhibitor either alone or in combination with an HDAC inhibitor, and optionally other anti-cancer agents. Such a period of time off between treatment periods is referred to herein as a time period of discontinuance. It is recognized that the length of the time period of discontinuance is dependent upon the degree of tumor response (i.e., complete versus partial) achieved with any prior treatment periods of therapy with these therapeutic agents.
Applications
[0095] One example of a cancer that is promoted by dysregulated Hh pathway signaling is basal cell carcinoma (BCC). BCC tumors have increased Gli levels, and molecularly targeted drugs against BCC have focused on antagonizing Smo and reducing Gli mRNA. One such example is cyclopamine, a plant alkaloid that inhibits Smo. Model systems (in vitro and in vivo) showed that cyclopamine effectively inhibited BCCs, but clinical applications of cyclopamine showed severe side effects that would preclude its use. Another Smo antagonist that has shown good efficacy in metastatic BCC tumors is vismodegib. Other treatments include surgery, chemotherapy, immunotherapy such as Euphorbia peplus, Imiquimod, Aldara, and radiation. In some instances, BCC is resistant to Smo antagonists because an activating mutation in the Hh pathway is downstream or epistatic to Smo, or the cancer cells have developed a resistance to Smo antagonists. The subject methods may be applied to such cancers.
[0096]
Another example of a disorder that is promoted by dysregulated Hh pathway signaling is Basal Cell Nevus Syndrome (BONS) also known as Gorlin Syndrome, a rare multi-system disease whose hallmark is the development of dozens to hundreds of BCCs.
Subjects who have BONS have inherited a defective copy of PTCH1. BONS is an orphan disease with a prevalence of 1 case per 56,000-164,000 in the population with no effective and tolerable treatments. Consequently, drugs that treat or prevent BCC tumors are of interest for subjects with BONS.
Another example of a disorder that is promoted by dysregulated Hh pathway signaling is Basal Cell Nevus Syndrome (BONS) also known as Gorlin Syndrome, a rare multi-system disease whose hallmark is the development of dozens to hundreds of BCCs.
Subjects who have BONS have inherited a defective copy of PTCH1. BONS is an orphan disease with a prevalence of 1 case per 56,000-164,000 in the population with no effective and tolerable treatments. Consequently, drugs that treat or prevent BCC tumors are of interest for subjects with BONS.
[0097] The subject methods and compositions find use in treating or preventing BCCs in two clinical populations: i) patients with hereditary BCC tumors, e.g., patients with Basal Cell Nevus Syndrome; and ii) patients in the general population with sporadic BCC
tumors. In the United States, BCC is the most common cancer diagnosed with 1 million new cases per year.
Though BCCs are rarely fatal, their high incidence and frequent recurrence in affected individuals can cause significant morbidity. Currently, the incidence of skin cancer is increasing yearly and treatment of skin cancer imposes a huge burden on national health services. Currently, there is no effective therapy for BCC prevention as sunscreens have not been shown to reduce BCC development in a randomized controlled trial.
tumors. In the United States, BCC is the most common cancer diagnosed with 1 million new cases per year.
Though BCCs are rarely fatal, their high incidence and frequent recurrence in affected individuals can cause significant morbidity. Currently, the incidence of skin cancer is increasing yearly and treatment of skin cancer imposes a huge burden on national health services. Currently, there is no effective therapy for BCC prevention as sunscreens have not been shown to reduce BCC development in a randomized controlled trial.
[0098]
Another example of a cancer that is promoted by dysregulated Hh pathway signaling is medulloblastoma. Medulloblastoma is a highly malignant primary brain tumor that originates in the cerebellum or posterior fossa. Medulloblastoma is the most common malignant brain tumor, comprising 14.5% of newly diagnosed cases. Medulloblastomas usually form in the vicinity of the fourth ventricle, between the brainstem and the cerebellum.
Known therapies for medulloblastoma include chemotherapy, e.g., one or more of lomustine, cisplatin, carboplatin, vincristine or cyclophosphamide, and vismodegib. The subject methods may be applied to medulloblastomas that are resistant to (or have developed a resistance to) Smo antagonists.
Another example of a cancer that is promoted by dysregulated Hh pathway signaling is medulloblastoma. Medulloblastoma is a highly malignant primary brain tumor that originates in the cerebellum or posterior fossa. Medulloblastoma is the most common malignant brain tumor, comprising 14.5% of newly diagnosed cases. Medulloblastomas usually form in the vicinity of the fourth ventricle, between the brainstem and the cerebellum.
Known therapies for medulloblastoma include chemotherapy, e.g., one or more of lomustine, cisplatin, carboplatin, vincristine or cyclophosphamide, and vismodegib. The subject methods may be applied to medulloblastomas that are resistant to (or have developed a resistance to) Smo antagonists.
[0099]
Another example of a cancer that is promoted by dysregulated Hh pathway signaling is rhabdomyosarcoma. Rhabdomyosarcoma is a sarcoma (cancer of connective tissues) in which the cancer cells are thought to arise from skeletal muscle progenitors.
It can be found in any anatomic location. Most occur in areas naturally lacking in skeletal muscle, such as the head, neck, and genitourinary tract. Diagnosis of rhabdomyosarcoma depends on recognition of differentiation toward skeletal muscle cells. The proteins myoD1 and myogenin are transcription factor proteins normally found in developing skeletal muscle cells which disappears after the muscle matures and becomes innervated by a nerve. Thus, myoD1 and myogenin are not usually found in normal skeletal muscle and serve as a useful immunohistochemical marker of rhabdomyosarcoma. Treatment for rhabdomyosarcoma consists of chemotherapy, radiation therapy and sometimes surgery.
Another example of a cancer that is promoted by dysregulated Hh pathway signaling is rhabdomyosarcoma. Rhabdomyosarcoma is a sarcoma (cancer of connective tissues) in which the cancer cells are thought to arise from skeletal muscle progenitors.
It can be found in any anatomic location. Most occur in areas naturally lacking in skeletal muscle, such as the head, neck, and genitourinary tract. Diagnosis of rhabdomyosarcoma depends on recognition of differentiation toward skeletal muscle cells. The proteins myoD1 and myogenin are transcription factor proteins normally found in developing skeletal muscle cells which disappears after the muscle matures and becomes innervated by a nerve. Thus, myoD1 and myogenin are not usually found in normal skeletal muscle and serve as a useful immunohistochemical marker of rhabdomyosarcoma. Treatment for rhabdomyosarcoma consists of chemotherapy, radiation therapy and sometimes surgery.
[00100]
Hedgehog pathway-dependent cancers in other tissues, including Hedgehog pathway-dependent cancer variants in other tissues that are resistant to Smo antagonists, may also be treated by the subject methods. These include, for example, subtypes of small cell lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer, and prostate cancer, all of which have been shown to respond to blocking agents of the hedgehog pathway.
Kits
Hedgehog pathway-dependent cancers in other tissues, including Hedgehog pathway-dependent cancer variants in other tissues that are resistant to Smo antagonists, may also be treated by the subject methods. These include, for example, subtypes of small cell lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer, and prostate cancer, all of which have been shown to respond to blocking agents of the hedgehog pathway.
Kits
[00101] Kits are provided comprising one or more containers holding compositions comprising at least one aPKC iota inhibitor (e.g., 0RT0422839 or 0RT0364436) and/or an HDAC inhibitor, and/or optionally one or more other anti-cancer agents for treating a hedgehog pathway-dependent cancer. Compositions can be in liquid form or can be lyophilized.
Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes.
Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes.
Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
[00102] The kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution.
It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices. The delivery device may be pre-filled with the compositions.
It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices. The delivery device may be pre-filled with the compositions.
[00103] The kit can also comprise a package insert containing written instructions for methods of using the compositions comprising the aPKC iota inhibitor and/or HDAC
inhibitor for treating a subject for a hedgehog pathway-dependent cancer. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body. Alternatively, instructions may be provided on a computer readable medium, e.g., diskette, CD, DVD, flash drive, etc., on which the information has been recorded, or the instructions may be presented at a website address, which may be used via the internet to access the information at a removed site. Any convenient means for providing instructions for treating a subject for a hedgehog pathway-dependent cancer may be present in the kits.
EXAMPLES
inhibitor for treating a subject for a hedgehog pathway-dependent cancer. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body. Alternatively, instructions may be provided on a computer readable medium, e.g., diskette, CD, DVD, flash drive, etc., on which the information has been recorded, or the instructions may be presented at a website address, which may be used via the internet to access the information at a removed site. Any convenient means for providing instructions for treating a subject for a hedgehog pathway-dependent cancer may be present in the kits.
EXAMPLES
[00104] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed.
Efforts have been made to ensure accuracy with respect to numbers used (e.g.
amounts, temperature, etc.) but some experimental errors and deviations should be accounted for.
Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
Efforts have been made to ensure accuracy with respect to numbers used (e.g.
amounts, temperature, etc.) but some experimental errors and deviations should be accounted for.
Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
[00105]
General methods in molecular and cellular biochemistry can be found in such standard textbooks as Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., HaRBor Laboratory Press 2001); Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999); Protein Methods (BoIlag et al., John Wiley & Sons 1996); Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy eds., Academic Press 1995); Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997); and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998), the disclosures of which are incorporated herein by reference. Reagents, cloning vectors, and kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, Sigma-Aldrich, and ClonTech.
Example 1 Hedgehog Pathway Modulation in BCC Cellular Models Introduction
General methods in molecular and cellular biochemistry can be found in such standard textbooks as Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., HaRBor Laboratory Press 2001); Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999); Protein Methods (BoIlag et al., John Wiley & Sons 1996); Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy eds., Academic Press 1995); Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997); and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998), the disclosures of which are incorporated herein by reference. Reagents, cloning vectors, and kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, Sigma-Aldrich, and ClonTech.
Example 1 Hedgehog Pathway Modulation in BCC Cellular Models Introduction
[00106] Basal cell carcinomas (BCCs) require high levels of Hedgehog (HH) signaling for survival and growth (Chang et al. (2012) Arch. Dermatol. 148(11):1324-1325, Atwood et al.
(2015) Cancer Cell 27(3):342-353, Atwood et al. (2013) Nature 494(7438):484-488, Hutchin et al. (2005) Genes Dev. 19(2):214-223). Activation of the HH pathway involves the HH ligand binding to Patched-1, thereby relieving inhibition of Smoothened (SMO). This results in activation of the GLI family of transcription factors, which ultimately promote transcription of HH target genes, including Gill itself. SMO inhibitors have recently been FDA
approved for BCC treatment, but drug resistance has emerged as a significant problem (Chang et al., supra;
Atwood et al. (2015), supra; Sekulic et al. (2012) N. Engl. J. Med.
366(23):2171-21791). As BCCs uniformly depend on the HH pathway for growth (Atwood et al. (2015), supra), resistant BCCs evolve to circumvent pharmacological blockade at the level of SMO using pathway-intrinsic mutations as well as noncanonical mechanisms of GLI activation (Atwood et al.
(2015), supra; Atwood et al. (2013), supra;).
(2015) Cancer Cell 27(3):342-353, Atwood et al. (2013) Nature 494(7438):484-488, Hutchin et al. (2005) Genes Dev. 19(2):214-223). Activation of the HH pathway involves the HH ligand binding to Patched-1, thereby relieving inhibition of Smoothened (SMO). This results in activation of the GLI family of transcription factors, which ultimately promote transcription of HH target genes, including Gill itself. SMO inhibitors have recently been FDA
approved for BCC treatment, but drug resistance has emerged as a significant problem (Chang et al., supra;
Atwood et al. (2015), supra; Sekulic et al. (2012) N. Engl. J. Med.
366(23):2171-21791). As BCCs uniformly depend on the HH pathway for growth (Atwood et al. (2015), supra), resistant BCCs evolve to circumvent pharmacological blockade at the level of SMO using pathway-intrinsic mutations as well as noncanonical mechanisms of GLI activation (Atwood et al.
(2015), supra; Atwood et al. (2013), supra;).
[00107]
Recently, we identified atypical PKC I/A (aPKC) overactivation as a powerful mechanism of drug resistance in BCC (Atwood et al. (2013), supra;). aPKC
phosphorylation of the GLI1 zinc-finger domain results in chromatin association, gene transcription, and HH
pathway activation downstream of inputs from SMO and Patched-1. Furthermore, GLI
promotes transcription of aPKC, forming another positive feedback loop with GLI.
Overactivation of this noncanonical HH signaling pathway drives pathway activation and vismodegib escape in advanced BCC (Atwood et al. (2013), supra;). Small-molecule inhibitors of aPKC, allosteric (Erdogan et al. (2006) J. Biol. Chem. 281(38):28450-28459) or orthosteric (Kjr et al. (2013) Biochem. J. 451(2):329-342), are in development but have not been applied to treat BCC.
Recently, we identified atypical PKC I/A (aPKC) overactivation as a powerful mechanism of drug resistance in BCC (Atwood et al. (2013), supra;). aPKC
phosphorylation of the GLI1 zinc-finger domain results in chromatin association, gene transcription, and HH
pathway activation downstream of inputs from SMO and Patched-1. Furthermore, GLI
promotes transcription of aPKC, forming another positive feedback loop with GLI.
Overactivation of this noncanonical HH signaling pathway drives pathway activation and vismodegib escape in advanced BCC (Atwood et al. (2013), supra;). Small-molecule inhibitors of aPKC, allosteric (Erdogan et al. (2006) J. Biol. Chem. 281(38):28450-28459) or orthosteric (Kjr et al. (2013) Biochem. J. 451(2):329-342), are in development but have not been applied to treat BCC.
[00108] GLI
proteins are further regulated, downstream of SMO, through acetylation by p300 and subsequent deacetylation. The deacetylation of GUI/2 at K518 and K757, respectively, by histone deacetylase 1/2 (HDAC1/2) is a critical step in the nuclear maturation process of GLI transcription factors required for chromatin association and gene transcription (Canettieri et al. (2010) Nat. Cell Biol. 12(2):132-142). HDAC1 is itself a transcriptional target of GLI, creating a third positive feedback loop of HH signaling. Of particular interest, HDAC inhibition has been proposed for the treatment of many HH-driven cancers (Canettieri et al., supra; Coni et al. (2017) Sci Rep. 7:44079; Zhao et al. (2014) Pharmacol. Res. Perspect.
2(3):e00043;
Coni et al. (2013) PLoS One 8(6):e65718). HDAC inhibitors block growth and promote apoptosis by altering the histone-DNA complex and by altering the acetylation status of nonhistone proteins (Falkenberg et al. (2014) Nat. Rev. Drug Discov. 13(9):673-691).
Vorinostat, a class I/II HDAC inhibitor, is currently FDA approved for the treatment of cutaneous lymphoma (Mann et al. (2007) Olin. Cancer Res. 13(8):2318-2322).
Unfortunately, HDAC inhibition has been hampered by its broadly cytotoxic nature. De novo drug discovery remains challenging due to the lack of validated targets and the cost of clinical development (Hoe!der et al. (2012) Mol. Oncol. 6(2):155-176).
proteins are further regulated, downstream of SMO, through acetylation by p300 and subsequent deacetylation. The deacetylation of GUI/2 at K518 and K757, respectively, by histone deacetylase 1/2 (HDAC1/2) is a critical step in the nuclear maturation process of GLI transcription factors required for chromatin association and gene transcription (Canettieri et al. (2010) Nat. Cell Biol. 12(2):132-142). HDAC1 is itself a transcriptional target of GLI, creating a third positive feedback loop of HH signaling. Of particular interest, HDAC inhibition has been proposed for the treatment of many HH-driven cancers (Canettieri et al., supra; Coni et al. (2017) Sci Rep. 7:44079; Zhao et al. (2014) Pharmacol. Res. Perspect.
2(3):e00043;
Coni et al. (2013) PLoS One 8(6):e65718). HDAC inhibitors block growth and promote apoptosis by altering the histone-DNA complex and by altering the acetylation status of nonhistone proteins (Falkenberg et al. (2014) Nat. Rev. Drug Discov. 13(9):673-691).
Vorinostat, a class I/II HDAC inhibitor, is currently FDA approved for the treatment of cutaneous lymphoma (Mann et al. (2007) Olin. Cancer Res. 13(8):2318-2322).
Unfortunately, HDAC inhibition has been hampered by its broadly cytotoxic nature. De novo drug discovery remains challenging due to the lack of validated targets and the cost of clinical development (Hoe!der et al. (2012) Mol. Oncol. 6(2):155-176).
[00109] Here we show that the aPKC iota inhibitors, 0R10422839 and 0R10364436, modulate BCC cell viability and reduce levels of GUI mRNA in line with GLI pathway modulation.
Results
Results
[00110] To study the efficacy of aPKC iota inhibition on BCCs in vitro, a murine BCC cell line was treated with increasing doses of 0RT0422839 or 0RT0364436. Treatment with either 0RT0422839 or 0RT0364436 resulted in a dose-dependent decrease in BCC growth and viability (FIGS. 10 and 1D). BCC viability was compared to that for treatment with the aPKC
inhibitors, PSI (FIG. 1A) and 0RT0329868 (FIG. 1B), as previously described by Mirza et al.
(JCI Insight (2017) 2(21) pii: e97071; herein incorporated by reference in its entirety).
Additionally, treatment with either 0RT0422839 or 0RT0364436 resulted in a dose-dependent decrease in levels of Glil mRNA (FIGS. 2A and 2B).
Example 2 Biochemical Kinase Assay of aPKC iota
inhibitors, PSI (FIG. 1A) and 0RT0329868 (FIG. 1B), as previously described by Mirza et al.
(JCI Insight (2017) 2(21) pii: e97071; herein incorporated by reference in its entirety).
Additionally, treatment with either 0RT0422839 or 0RT0364436 resulted in a dose-dependent decrease in levels of Glil mRNA (FIGS. 2A and 2B).
Example 2 Biochemical Kinase Assay of aPKC iota
[00111] The ability of compounds to inhibit the kinase activity of aPKC iota is measured using the IMAP FP progressive binding system (Molecular Devices R8127) in 384-well black, nonbinding, flat-bottom assay plates (Corning 3575). The assay mixture (final volume = 10 pl) contains 20 mM Tris-HCL (pH 7.5), 150 pM ATP, 10 mM MgCl2, 0.01% Triton X-100, 250 pM
EGTA, 1 mM DTT, 15 pM PKCI (EMD Millipore 14-505), 100 nM FAM-PKCE-pseudosubstrate (Molecular Devices RP7548), 0.1% DMSO, and various concentrations of the test compounds, 0RT0422839 and 0RT0364436. Compound dilutions (prepared in 100% DMSO) are added to the assay plate at 100 nl using the BioMek NX pin tool (Beckman Coulter).
Enzyme reactions are initiated by the addition of ATP (MilliporeSigma A7699), followed by incubation of the plates for 1 hour in a 25 C incubator. A 20- pl aliquot of IMAP
detection reagent (1:400 in 85% 1X Binding Buffer A and 15% 1X Binding Buffer B) is added to each well, followed by a 2-hour incubation at 25 C. FP is then measured using the PerkinElmer Envision 2102 multi-label plate reader (PerkinElmer) using the FP dual mirror, FP480 excitation filter, and P-pol 535 and S-pol 535 emission filters. Data analysis is performed using ActivityBase (IDBS).1050 values are calculated by plotting the percentage inhibition versus log10 of the concentration of the compound and fitting to a 4-parameter logistic model (top and bottom constrained to 100 and 0, respectively) in XLFit 4 (IDBS).
EGTA, 1 mM DTT, 15 pM PKCI (EMD Millipore 14-505), 100 nM FAM-PKCE-pseudosubstrate (Molecular Devices RP7548), 0.1% DMSO, and various concentrations of the test compounds, 0RT0422839 and 0RT0364436. Compound dilutions (prepared in 100% DMSO) are added to the assay plate at 100 nl using the BioMek NX pin tool (Beckman Coulter).
Enzyme reactions are initiated by the addition of ATP (MilliporeSigma A7699), followed by incubation of the plates for 1 hour in a 25 C incubator. A 20- pl aliquot of IMAP
detection reagent (1:400 in 85% 1X Binding Buffer A and 15% 1X Binding Buffer B) is added to each well, followed by a 2-hour incubation at 25 C. FP is then measured using the PerkinElmer Envision 2102 multi-label plate reader (PerkinElmer) using the FP dual mirror, FP480 excitation filter, and P-pol 535 and S-pol 535 emission filters. Data analysis is performed using ActivityBase (IDBS).1050 values are calculated by plotting the percentage inhibition versus log10 of the concentration of the compound and fitting to a 4-parameter logistic model (top and bottom constrained to 100 and 0, respectively) in XLFit 4 (IDBS).
[00112] The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions.
Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention is embodied by the appended claims.
Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention is embodied by the appended claims.
Claims (30)
1. A method of treating a subject for a hedgehog pathway-dependent cancer, the method comprising administering to the subject a therapeutically effective amount of a composition comprising 0RT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1, wherein the cancer is basal cell carcinoma (BCC).
3. The method of claim 1 or 2, wherein the cancer comprises a constitutively active hedgehog pathway.
4. The method of any one of claims 1 to 3, wherein the cancer is metastatic.
5. The method of any one of claims 1 to 4, wherein multiple cycles of treatment are administered to the subject for a time period sufficient to effect at least a partial tumor response.
6. The method of claim 5, wherein the time period is at least 6 months.
7. The method of claim 6, wherein the time period is at least 12 months.
8. The method of any one of claims 5 to 7, wherein multiple cycles of treatment are administered to the subject for a time period sufficient to effect a complete tumor response.
9. The method of any one of claims 5 to 8, wherein the composition is administered according to a daily dosing regimen or intermittently.
10. The method of any one of claims 1 to 9, further comprising administering additional anti-cancer therapy.
11. The method of claim 10, wherein the additional anti-cancer therapy is surgery, chemotherapy, radiation therapy, immunotherapy, biologic therapy, or a combination thereof.
12. The method of any one of claims 1 to 11, wherein the composition further comprises a pharmaceutically acceptable excipient.
13. The method of any one of claims 1 to 12, further comprising administering a histone deacetylase (HDAC) inhibitor in combination with the CRT0422839 or CRT0364436, or the pharmaceutically acceptable salt thereof.
14. The method of claim 13, wherein the HDAC inhibitor is vorinostat.
15. The method of any one of claims 1 to 14, wherein the subject is mammalian.
16. The method of claim 15, wherein the subject is human.
17. The method of any one of claims 1 to 16, wherein the CRT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce viability of hedgehog pathway-dependent cancerous cells in the subject.
18. The method of any one of claims 1 to 17, wherein the CRT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce production of Gli 1 mRNA in hedgehog pathway-dependent cancerous cells in the subject.
19. The method of any one of claims 1 to 18, wherein the CRT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to reduce growth and cell proliferation of hedgehog pathway-dependent cancerous cells in the subject.
20. A method of inhibiting growth or proliferation of a hedgehog pathway-dependent cancerous cell, the method comprising contacting the hedgehog pathway-dependent cancerous cell with an effective amount of CRT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof.
21. The method according to claim 20, wherein the hedgehog pathway-dependent cancerous cell is a basal cell carcinoma (BCC) cell.
22. The method of claim 20 or 21, wherein the hedgehog pathway-dependent cancerous cell comprises a constitutively active hedgehog pathway.
23. The method of any one of claims 20 to 22, wherein the hedgehog pathway-dependent cancerous cell is in vivo or in vitro.
24. The method of any one of claims 20 to 23, wherein the hedgehog pathway-dependent cancerous cell is a human cancerous cell.
25. The method of any one of claims 20 to 24, further comprising contacting the hedgehog pathway-dependent cancerous cell with a deacetylase (HDAC) inhibitor.
26. The method of claim 25, wherein the HDAC inhibitor is vorinostat.
27. A composition comprising CRT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof, for use in the treatment of a hedgehog pathway-dependent cancer.
28. The composition of claim 27, wherein the cancer is basal cell carcinoma (BCC).
29. The composition of claim 27 or 28, further comprising a histone deacetylase (HDAC) inhibitor.
30. The composition of claim 29, wherein the HDAC inhibitor is vorinostat.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962825334P | 2019-03-28 | 2019-03-28 | |
US62/825,334 | 2019-03-28 | ||
PCT/US2020/025437 WO2020198670A1 (en) | 2019-03-28 | 2020-03-27 | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3135196A1 true CA3135196A1 (en) | 2020-10-01 |
Family
ID=72611927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3135196A Pending CA3135196A1 (en) | 2019-03-28 | 2020-03-27 | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220143028A1 (en) |
EP (1) | EP3947380A4 (en) |
JP (1) | JP2022527320A (en) |
KR (1) | KR20220002930A (en) |
CN (1) | CN114206865A (en) |
AU (1) | AU2020248096A1 (en) |
BR (1) | BR112021019204A2 (en) |
CA (1) | CA3135196A1 (en) |
IL (1) | IL286699A (en) |
MX (1) | MX2021011788A (en) |
SG (1) | SG11202110270YA (en) |
WO (1) | WO2020198670A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012154300A1 (en) * | 2011-05-06 | 2012-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of atypical protein kinase c and their use |
CN105102456B (en) * | 2012-09-28 | 2017-11-14 | 癌症研究技术有限公司 | The azepine quinazoline inhibitor of Atypical protein kinase C |
US9192609B2 (en) * | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
TWI675836B (en) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | Azaquinazoline inhibitors of atypical protein kinase c |
JP2020530467A (en) * | 2017-08-11 | 2020-10-22 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | How to Target Kinases to Treat Cancer Metastases |
-
2020
- 2020-03-27 CN CN202080039400.7A patent/CN114206865A/en active Pending
- 2020-03-27 CA CA3135196A patent/CA3135196A1/en active Pending
- 2020-03-27 AU AU2020248096A patent/AU2020248096A1/en active Pending
- 2020-03-27 US US17/598,719 patent/US20220143028A1/en active Pending
- 2020-03-27 JP JP2021558519A patent/JP2022527320A/en active Pending
- 2020-03-27 WO PCT/US2020/025437 patent/WO2020198670A1/en unknown
- 2020-03-27 EP EP20779899.2A patent/EP3947380A4/en active Pending
- 2020-03-27 SG SG11202110270YA patent/SG11202110270YA/en unknown
- 2020-03-27 BR BR112021019204A patent/BR112021019204A2/en unknown
- 2020-03-27 KR KR1020217035054A patent/KR20220002930A/en unknown
- 2020-03-27 MX MX2021011788A patent/MX2021011788A/en unknown
-
2021
- 2021-09-26 IL IL286699A patent/IL286699A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021019204A2 (en) | 2021-11-30 |
MX2021011788A (en) | 2022-01-24 |
JP2022527320A (en) | 2022-06-01 |
EP3947380A1 (en) | 2022-02-09 |
WO2020198670A9 (en) | 2020-11-19 |
EP3947380A4 (en) | 2023-01-11 |
US20220143028A1 (en) | 2022-05-12 |
CN114206865A (en) | 2022-03-18 |
WO2020198670A1 (en) | 2020-10-01 |
KR20220002930A (en) | 2022-01-07 |
AU2020248096A1 (en) | 2021-10-14 |
SG11202110270YA (en) | 2021-10-28 |
IL286699A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Taves et al. | Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord | |
Melemedjian et al. | mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK | |
Bai et al. | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme | |
Shaw et al. | Not too little, not too much—just right!(Better ways to give high dose melphalan) | |
US10278954B2 (en) | Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor | |
AU2013329121A1 (en) | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence | |
US20150335702A1 (en) | Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers | |
Jones et al. | Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions | |
BR122020006408B1 (en) | UNIT DOSE OF COLONY-FORMING UNITS OF C. NOVYI, PHARMACEUTICAL COMPOSITION AND USE OF C. NOVYI NT TO TREAT OR MITIGATE AN EFFECT OF A SOLID TUMOR PRESENT IN A HUMAN BEING | |
EP2143429B1 (en) | Use of cilastatin to reduce the nephrotoxicity of different compounds | |
US20130323283A1 (en) | Compositions and methods for treating foxp3+ treg related diseases | |
Sasaki et al. | Convection-enhanced delivery of enhancer of zeste homolog-2 (EZH2) inhibitor for the treatment of diffuse intrinsic pontine glioma | |
Moreira et al. | Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine | |
Liu et al. | UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer | |
Richards et al. | The cellular pathways and potential therapeutics of Polycystic Kidney Disease | |
Feng et al. | FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway | |
WO2013079580A1 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
US20220143028A1 (en) | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers | |
Nakashima et al. | Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats | |
López-Iglesias et al. | Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone | |
Zhu et al. | Effects of ropivacaine on adhesion molecule CD11b expression and function in human neutrophils | |
US20210137898A1 (en) | Methods to treat gliomas using a stat3 inhibitor | |
Xia et al. | A cell‐penetrating peptide exerts therapeutic effects against ischemic stroke by mediating the lysosomal degradation of sirtuin 5 | |
SE1851333A1 (en) | Treatment of osteoarthritis | |
US20090197947A1 (en) | Medicaments and methods for lowering plasma lipid levels and screening drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220822 |
|
EEER | Examination request |
Effective date: 20220822 |
|
EEER | Examination request |
Effective date: 20220822 |
|
EEER | Examination request |
Effective date: 20220822 |
|
EEER | Examination request |
Effective date: 20220822 |
|
EEER | Examination request |
Effective date: 20220822 |
|
EEER | Examination request |
Effective date: 20220822 |